Altimmune (NASDAQ:ALT) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT - Free Report) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $12.00 target price on the stock.

Several other research firms also recently issued reports on ALT. Stifel Nicolaus initiated coverage on Altimmune in a research report on Wednesday, January 8th. They issued a "buy" rating and a $18.00 target price on the stock. UBS Group initiated coverage on Altimmune in a report on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $20.83.

Altimmune Trading Down 3.6 %

Altimmune stock traded down $0.25 during midday trading on Wednesday, reaching $6.66. The company's stock had a trading volume of 1,440,025 shares, compared to its average volume of 1,940,553. Altimmune has a 52-week low of $5.28 and a 52-week high of $14.84. The stock's 50-day simple moving average is $7.59 and its 200-day simple moving average is $7.18.

Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million during the quarter. During the same quarter last year, the business earned ($0.39) earnings per share. On average, research analysts anticipate that Altimmune will post -1.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Altimmune

Several institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its holdings in Altimmune by 142.9% during the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company's stock worth $3,791,000 after buying an additional 335,444 shares in the last quarter. Bellevue Group AG increased its holdings in Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company's stock valued at $5,303,000 after buying an additional 263,660 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Altimmune in the third quarter worth about $674,000. Exchange Traded Concepts LLC boosted its stake in shares of Altimmune by 74.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company's stock worth $1,331,000 after acquiring an additional 92,498 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company's stock valued at $956,000 after acquiring an additional 75,064 shares during the period. Institutional investors and hedge funds own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.